{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:06:17Z","timestamp":1795010777216,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.oret.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:19:15Z","timestamp":1737400755000},"page":"625-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Macular Atrophy in Neovascular Age-related Macular Degeneration"],"prefix":"10.1016","volume":"9","author":[{"given":"Alessandro","family":"Berni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Coletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.01.011_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.01.011_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamaophthalmol.2020.5044","article-title":"Insights from survival analyses during 12 years of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"139","author":"Fu","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1159\/000519518","article-title":"Complications associated with worse visual outcomes in patients with exudative neovascular age-related macular degeneration","volume":"244","author":"Barresi","year":"2021","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.01.011_bib6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.oret.2018.04.009","article-title":"Atrophy in neovascular age-related macular degeneration: Age-Related Eye Disease Study 2 report number 15","volume":"2","author":"Domalpally","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","article-title":"The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration","volume":"3","author":"Cheung","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2019.09.030","article-title":"Spectral-domain OCT\u2013based prevalence and progression of macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"127","author":"Gune","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.oret.2022.03.010","article-title":"Long-term retinal morphology and functional associations in treated neovascular age-related macular degeneration: findings from the inhibition of VEGF in age-related choroidal neovascularisation trial","volume":"6","author":"Peto","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/bjophthalmol-2021-319602","article-title":"Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy","volume":"107","author":"Fang","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1167\/iovs.65.1.44","article-title":"Relationship of topographic distribution of macular atrophy secondary to neovascular AMD and reading performance","volume":"65","author":"Ricardi","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.01.011_bib13","article-title":"Interreader and intermodality variability in macular atrophy quantification in neovascular age-related macular degeneration: comparison of 6 imaging modalities","author":"Borrelli","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/IAE.0b013e3182657fff","article-title":"Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy","volume":"33","author":"Lois","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/iovs.65.3.18","article-title":"Distinct pathways of macular atrophy in type 3 macular neovascularization associated with AMD","volume":"65","author":"Borrelli","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.01.011_bib17","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/s41433-022-02332-8","article-title":"Two potentially distinct pathways to geographic atrophy in age-related macular degeneration characterized by quantitative fundus autofluorescence","volume":"37","author":"Wei","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.01.011_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40123-019-00227-8","article-title":"A review of macular atrophy of the retinal pigment epithelium in patients with neovascular age-related macular degeneration: what is the link? Part II","volume":"9","author":"Horani","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2025.01.011_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000520171","article-title":"Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment","volume":"245","author":"Foss","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.01.011_bib20","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2025.01.011_bib22","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2025.01.011_bib23","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2025.01.011_bib24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib25","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"10.1016\/j.oret.2025.01.011_bib26","series-title":"RStudio: Integrated Development for R","year":"2020"},{"key":"10.1016\/j.oret.2025.01.011_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.oret.2025.01.011_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","article-title":"Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation","volume":"159","author":"Cho","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1167\/iovs.15-18837","article-title":"Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation","volume":"57","author":"Baek","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.01.011_bib32","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","article-title":"Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy","volume":"36","author":"Abdelfattah","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00417-015-2993-3","article-title":"Long-term visual outcome and prognostic factors of intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation","volume":"254","author":"Cho","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib34","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","article-title":"Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR study","volume":"123","author":"Sarraf","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib36","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/IAE.0000000000002054","article-title":"Macular atrophy incidence in anti-vascular endothelial growth factor\u2013treated neovascular age-related macular degeneration: risk factor evaluation for individualized treatment need of ranibizumab or aflibercept according to an observe-and-plan regimen","volume":"39","author":"Mantel","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000492924","article-title":"Onset of retinal pigment epithelium atrophy subsequent to anti-VEGF therapy in patients with neovascular age-related macular degeneration","volume":"241","author":"Sitnilska","year":"2019","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.01.011_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232353","article-title":"Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration","volume":"15","author":"Eng","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.01.011_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s10384-020-00745-0","article-title":"Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study","volume":"64","author":"Koizumi","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib42","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","article-title":"Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with vascular endothelial growth factor inhibitors using a treat-and-extend or a pro re nata regimen: four-year results of the MANEX study","volume":"127","author":"Spooner","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738521","article-title":"Inflammatory factors of macular atrophy in eyes with neovascular age-related macular degeneration treated with aflibercept","volume":"12","author":"Sato","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.oret.2025.01.011_bib44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000520595","article-title":"Progression of macular atrophy in patients receiving long-term anti-VEGF therapy for age-related macular degeneration: real-life data","volume":"245","author":"Blazaki","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.01.011_bib45","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41598-022-07108-4","article-title":"Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment","volume":"12","author":"Cho","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.01.011_bib46","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/bjophthalmol-2021-320047","article-title":"Characterisation of the vascular anterior surface of type 1 macular neovascularisation after anti-VEGF therapy","volume":"107","author":"Corvi","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.oret.2023.03.004","article-title":"Prevalence of macular atrophy in the MARINA study of ranibizumab versus sham for neovascular age-related macular degeneration","volume":"7","author":"Blodi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib48","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.oret.2022.11.002","article-title":"Characteristics that correlate with macular atrophy in ranibizumab-treated patients with neovascular age-related macular degeneration","volume":"7","author":"Staurenghi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib49","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib50","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.01.011_bib51","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.01.011_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.011_bib53","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1097\/IAE.0000000000002198","article-title":"Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration","volume":"38","author":"Borrelli","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib54","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/IAE.0000000000001766","article-title":"Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti\u2013vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis","volume":"38","author":"Christenbury","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.011_bib55","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","article-title":"Choroidal neovascularization","volume":"137","author":"Grossniklaus","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.011_bib56","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:10:40Z","timestamp":1777633840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2468653025000132"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.011","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macular Atrophy in Neovascular Age-related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00c2\u00a9 2025 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}